Sellas’ NeuVax + Herceptin combination treatment shows significant effect in breast cancer trial

This article was originally published here

Sellas Life Sciences Group has reported a positive interim data from the prospective, randomized, single-blinded, controlled Phase 2b independent investigator-sponsored clinical trial (IST) of trastuzumab (Herceptin) +/- nelipepimut-S (NeuVax™) in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply